ストックスクリーナーアプリを入手
5.22
1.14%
-0.06
前日終値:
$5.28
開ける：
$5.23
24時間の取引高:
585.38K
Relative Volume:
0.43
時価総額：
$513.24M
収益：
$20.65M
当期純損益:
$-192.65M
株価収益率:
-2.0154
EPS:
-2.59
ネットキャッシュフロー:
$-134.39M
1週間 パフォーマンス:
-5.95%
1か月 パフォーマンス:
-15.81%
6か月 パフォーマンス:
+4.82%
1年 パフォーマンス:
-60.69%
1日の値動き範囲:
$5.15
$5.3955
1週間の範囲:
$5.15
$5.99
52週間の値動き範囲:
$4.305
$13.24
Verve Therapeutics Inc Stock (VERV) Company Profile
VERV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
5.22 | 513.24M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2023-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-10-06 | 開始されました | Credit Suisse | Neutral |
| 2022-08-25 | アップグレード | Stifel | Hold → Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-09-24 | 開始されました | Stifel | Hold |
| 2021-07-12 | 開始されました | Guggenheim | Buy |
| 2021-07-12 | 開始されました | JP Morgan | Neutral |
| 2021-07-12 | 開始されました | Jefferies | Buy |
| 2021-07-12 | 開始されました | William Blair | Outperform |
すべてを表示
Verve Therapeutics Inc (VERV) 最新ニュース
Investigation announced for Long-Term Investors in shares - openPR
Pixalate Releases Q4 2024 United Kingdom Connected TV (CTV) Ad Supply Chain Trends Report: Samsung Smart TV Leads in Device Market Share (30%); Ad Fraud (IVT) Rate Hits 16% - GlobeNewswire Inc.
Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts - Seeking Alpha
Verve Therapeutics Announces Clearance of Investigational - GlobeNewswire
Verve Therapeutics Says US FDA Clears Verve-102 IND Application for Premature Coronary Artery Disease - Marketscreener.com
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose - The Manila Times
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by Arizona State Retirement System - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by US Bancorp DE - Defense World
Verve Therapeutics Inc (VERV): Significant Improvements, Worth Considering - Stocks Register
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Rhumbline Advisers - Defense World
IFP Advisors Inc Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
(VERV) Technical Data - Stock Traders Daily
Verve Therapeutics (NASDAQ:VERV) Shares Gap Down After Analyst Downgrade - Defense World
Verve Therapeutics (NASDAQ:VERV) Price Target Cut to $15.00 by Analysts at Royal Bank of Canada - Defense World
Verve Therapeutics price target lowered to $15 from $17 at RBC Capital - TipRanks
RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk - Marketscreener.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
How Verve Therapeutics Is Attracting Talent: New Equity Compensation Package Details - StockTitan
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Analysts Set Expectations for VERV Q1 Earnings - Defense World
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
HC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) Stock - Defense World
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright lifts VERVE Therapeutics price target to $15 By Investing.com - Investing.com Canada
Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity - TipRanks
Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - News & Insights
Verve TherapeuticsKey Data Catalysts, Major Share Price Volatility In Play In Q2 - Seeking Alpha
Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position - TipRanks
Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts - TipRanks
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Verve Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance UK
Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Verve Therapeutics: Q4 Earnings Snapshot - Houston Chronicle
Verve Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Verve Therapeutics reports Q4 EPS (58c), consensus (67c) - TipRanks
Vertex ends gene editing research pact with Verve - BioPharma Dive
Verve Therapeutics, Inc. SEC 10-K Report - TradingView
Verve Therapeutics: Q4 Earnings Snapshot -February 27, 2025 at 07:33 am EST - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Can Verve's Gene Editing Trials Deliver? Key PCSK9 Data Coming in 2025 With $524M War Chest - StockTitan
VERV STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVERV - ACCESS Newswire
How To Trade (VERV) - Stock Traders Daily
William Blair Reaffirms Outperform Rating for Verve Therapeutics (NASDAQ:VERV) - Defense World
Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Tuesday - Defense World
Verve Therapeutics Inc (VERV) 財務データ
収益
当期純利益
現金流量
EPS
Verve Therapeutics Inc (VERV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kathiresan Sekar | Chief Executive Officer |
Jun 28 '24 |
Option Exercise |
2.87 |
30,000 |
86,100 |
351,128 |
| Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '24 |
Sale |
8.24 |
1,514 |
12,475 |
8,659 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):